Subthalamotomy in the treatment of Parkinson's disease: Clinical aspects and mechanisms of action - A review

Journal of Neurosurgery

Volumn 120, Issue 1, 2014, Pages 140-151

  Jourdain, Vincent A ^a,b   Schechtmann, Gastón ^c   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Functional neurosurgery; Hemiballismus; Lesion; Levodopa induced dyskinesia; Parkinson's disease; Subthalamic nucleus; Subthalamotomy; Surgical therapy

Indexed keywords

LEVODOPA;

BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COGNITION; DYSKINESIA; HEMIBALLISM; HUMAN; NEUROCHEMISTRY; NEUROPHYSIOLOGY; NEUROPROTECTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUBTHALAMIC NUCLEUS; SUBTHALAMOTOMY; SURGICAL TECHNIQUE; THALAMOTOMY;

HUMANS; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

EID: 84892384092     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2013.10.JNS13332     Document Type: Review

References (192)

1. Abosch A, Timmermann L, Bartley S, Rietkerk HG, Whiting D, Connolly PJ, et al: An international survey of deep brain stimulation procedural steps. Stereotact Funct Neurosurg 91:1-11, 2013
2. Absher JR, Vogt BA, Clark DG, Flowers DL, Gorman DG, Keyes JW, et al: Hypersexuality and hemiballism due to subthalamic infarction. Neuropsychiatry Neuropsychol Behav Neurol 13:220-229, 2000
3. Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458, 2001
4. Albin RL, Greenamyre JT: Alternative excitotoxic hypotheses. Neurology 42:733-738, 1992
5. Alvarez Gonzalez L, Macias R, Guridi J, Lopez G, Maragoto C, Teijeiro J, et al: Dorsal subthalamotomy for Parkinson's disease. Ann Neurol 46:492-493, 1999
6. Alvarez L, Macias R, Guridi J, Lopez G, Alvarez E, Maragoto C, et al: Dorsal subthalamotomy for Parkinson's disease. Mov Disord 16:72-78, 2001
7. Alvarez L, Macias R, Lopez G, Alvarez E, Pavon N, Rodriguez-Oroz MC, et al: Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. Brain 128:570-583, 2005
8. Alvarez L, Macias R, Pavón N, López G, Rodríguez- Oroz MC, Rodríguez R, et al: Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. J Neurol Neurosurg Psychiatry 80:979-985, 2009
9. Alvarez L, Macias R, Pavon N, Rodriguez MCO, Obeso JA: Motor and cognitive effects of subthalamic nucleotomy in one hundred patients with Parkinson's disease. Mov Disord 24 Suppl 1:S457, 2009 (Abstract)
10. Andrén PE, Levin ED, Liminga U, Gunne L: Behavioral and neurochemical consequences of ibotenic acid lesion in the subthalamic nucleus of the common marmoset. Brain Res Bull 36:301-307, 1995
11. Andy OJ: Diencephalic coagulation in the treatment of hemiballismus. Confin Neurol 22:346-350, 1962
12. Andy OJ, Browne JS: Diencephalic coagulation in the treatment of hemiballismus. Surg Forum 10:795-799, 1960
13. Andy OJ, Jurko MF: Alteration in Parkinson tremor during electrode insertion. Confin Neurol 26:378-381, 1965
14. Andy OJ, Jurko MF, Sias FR Jr: Subthalamotomy in treatment of Parkinsonian tremor. J Neurosurg 20:860-870, 1963
15. Aristieta A, Azkona G, Sagarduy A, Miguelez C, Ruiz-Ortega JA, Sanchez-Pernaute R, et al: The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats. PLoS ONE 7:e42652, 2012
16. Aziz TZ, Nandi D, Parkin S, Liu X, Giladi N, Bain P, et al: Targeting the subthalamic nucleus. Stereotact Funct Neurosurg 77:87-90, 2001
17. Aziz TZ, Peggs D, Agarwal E, Sambrook MA, Crossman AR: Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-exposed primate. Br J Neurosurg 6:575-582, 1992
18. Aziz TZ, Peggs D, Sambrook MA, Crossman AR: Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phe-nyl- 1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 6:288-292, 1991
19. Bacci JJ, Absi H, Manrique C, Baunez C, Salin P, Kerkerian-Le Goff L: Differential effects of prolonged high frequency stimulation and of excitotoxic lesion of the subthalamic nucleus on dopamine denervation-induced cellular defects in the rat striatum and globus pallidus. Eur J Neurosci 20:3331-3341, 2004
20. Barlas O, Hanaǧasi HA, Imer M, Sahin HA, Sencer S, Emre M: Do unilateral ablative lesions of the subthalamic nucleu in parkinsonian patients lead to hemiballism? Mov Disord 16: 306-310, 2001
21. Baron MS, Wichmann T, Ma D, DeLong MR: Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J Neurosci 22:592-599, 2002
22. Benabid AL, Chabardes S, Mitrofanis J, Pollak P: Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 8:67-81, 2009
23. Bergman H, Wichmann T, DeLong MR: Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438, 1990
24. Bertrand C, Hardy J, Molina-Negro P, Martinez N: Optimum physiological target for the arrest of tremor, in Gillingham FJ, Donaldson IML (eds): Third Symposium on Parkinson's Disease. Edinburgh: Livingstone, 1969, pp 251-259
25. Bickel S, Alvarez L, Macias R, Pavon N, Leon M, Fernandez C, et al: Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson's disease. Parkinsonism Relat Disord 16:535-539, 2010
26. Bilbao G, Ruiz-Ortega JA, Miguens N, Ulibarri I, Linazasoro G, Gómez-Urquijo S, et al: Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment. Brain Res 1084:175-184, 2006
27. Blandini F, Garcia-Osuna M, Greenamyre JT: Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats. Eur J Neurosci 9:1407-1413, 1997
28. Blandini F, Greenamyre JT: Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. Brain Res 669:59-66, 1995
29. Blandini F, Porter RH, Greenamyre JT: Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. Neurosci Lett 186:99-102, 1995
30. Boraud T, Bezard E, Guehl D, Bioulac B, Gross C: Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res 787:157-160, 1998
31. Brouillet E, Beal MF: NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport 4: 387-390, 1993
32. Burbaud P, Gross C, Benazzouz A, Coussemacq M, Bioulac B: Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons. Exp Brain Res 105:48-58, 1995
33. Butler EG, Bourke DW, Finkelstein DI, Horne MK: The effects of reversible inactivation of the subthalamo-pallidal pathway on the behaviour of naive and hemiparkinsonian monkeys. J Clin Neurosci 4:218-227, 1997
34. Carpenter MB: Ballism associated with partial destruction of the subthalamic nucleus of luys. Neurology 5:479-489, 1955
35. Carpenter MB, Whittier JR, Mettler FA: Analysis of choreoid hyperkinesia in the Rhesus monkey; surgical and pharmacological analysis of hyperkinesia resulting from lesions in the subthalamic nucleus of Luys. J Comp Neurol 92:293-331, 1950
36. Carvalho GA, Nikkhah G: Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp Neurol 171:405-417, 2001
37. Centonze D, Gubellini P, Rossi S, Picconi B, Pisani A, Bernardi G, et al: Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. Neuroscience 133:831-840, 2005
38. Cerquetti D, Obeso JA, Merello M: Neuronal discharge patterns in the globus pallidus pars interna in a patient with Parkinson's disease and hemiballismus secondary to subthalamotomy. Exp Brain Res 213:447-455, 2011
39. Chen CC, Lee ST, Wu T, Chen CJ, Huang CC, Lu CS: Hemiballism after subthalamotomy in patients with Parkinson's disease: report of 2 cases. Mov Disord 17:1367-1371, 2002
40. Chen L, Liu Z, Tian Z, Wang Y, Li S: Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions. Stereotact Funct Neurosurg 75:66-75, 2000
41. Coban A, Hanagasi HA, Karamursel S, Barlas O: Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease. Br J Neurosurg 23:23-29, 2009
42. Crozier S, Lehéricy S, Verstichel P, Masson C, Masson M: Transient hemiballism/hemichorea due to an ipsilateral subthalamic nucleus infarction. Neurology 46:267-268, 1996
43. De Bie RM, Schuurman PR, Esselink RAJ, Bosch DA, Speelman JD: Bilateral pallidotomy in Parkinson's disease: a retrospective study. Mov Disord 17:533-538, 2002
44. Delfs JM, Ciaramitaro VM, Parry TJ, Chesselet MF: Subthalamic nucleus lesions: widespread effects on changes in gene expression induced by nigrostriatal dopamine depletion in rats. J Neurosci 15:6562-6575, 1995
45. Deligny C, Drapier S, Verin M, Lajat Y, Raoul S, Damier P: Bilateral subthalamotomy through DBS electrodes: a rescue option for device-related infection. Neurology 73:1243-1244, 2009
46. Dewey RB Jr, Jankovic J: Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol 46:862-867, 1989
47. Diederich N, Goetz CG, Stebbins GT, Klawans HL, Nittner K, Koulosakis A, et al: Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology 42:1311-1314, 1992
48. Dierssen G, Gioino GG, Cooper IS: Participation of ipsilateral hemisphere lesions in the pathology of hemichorea and hemiballismus. Neurology 11:894-898, 1961
49. Doshi P, Bhatt M: Hemiballism during subthalamic nucleus lesioning. Mov Disord 17:848-849, 2002
50. Eskandar EN, Flaherty A, Cosgrove GR, Shinobu LA, Barker FG II: Surgery for Parkinson disease in the United States, 1996 to 2000: practice patterns, short-term outcomes, and hospital charges in a nationwide sample. J Neurosurg 99:863-871, 2003
51. Etemadifar M, Abtahi SH, Abtahi SM, Mirdamadi M, Sajjadi S, Golabbakhsh A, et al: Hemiballismus, hyperphagia, and behavioral changes following subthalamic infarct. Case Rep Med 2012:768580, 2012
52. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al: Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508, 2004
53. Fasano A, Daniele A, Albanese A: Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 11:429-442, 2012
54. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al: The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 26 (Suppl 3):S2-S41, 2011
55. Ghika J, Ghika-Schmid F, Fankhauser H, Assal G, Vingerhoets F, Albanese A, et al: Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. J Neurosurg 91:313-321, 1999
56. Ghika-Schmid F, Ghika J, Regli F, Bogousslavsky J: Hyperkinetic movement disorders during and after acute stroke: the Lausanne Stroke Registry. J Neurol Sci 146:109-116, 1997
57. Gill SS, Heywood P: Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. Lancet 350:1224, 1997
58. Gill SS, Heywood P: Bilateral subthalamic nucleotomy can be accomplished safely. Mov Disord 13 (Suppl 2):201, 1998
59. Gill SS, Heywood P: Subthalamic nucleus lesions, in Lozano AM (ed): Movement Disorder Surgery. Basel: Karger, 2000, Vol 15, pp 188-195
60. Gilmour TP, Lieu CA, Nolt MJ, Piallat B, Deogaonkar M, Subramanian T: The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys. Exp Neurol 228:53-58, 2011
61. Grandas F: Hemiballismus, in Weiner WJ, Tolosa E (eds): Handbook of Clinical Neurology: Hyperkinetic Movement Disorders. Amsterdam: Elsevier, 2011, Vol 100, pp 249-260
62. Greene JG, Greenamyre JT: Bioenergetics and glutamate excitotoxicity. Prog Neurobiol 48:613-634, 1996
63. Guridi J, Herrero MT, Luquin MR, Guillén J, Ruberg M, Laguna J, et al: Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 119:1717-1727, 1996
64. Guridi J, Herrero MT, Luquin R, Guillen J, Obeso JA: Subthalamotomy improves MPTP-induced parkinsonism in monkeys. Stereotact Funct Neurosurg 62:98-102, 1994
65. Guridi J, Obeso JA: The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain 124:5-19, 2001
66. Hamada I, DeLong MR: Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding. J Neurophysiol 68:1859-1866, 1992
67. Hammond C, Feger J, Bioulac B, Souteyrand JP: Experimental hemiballism in the monkey produced by unilateral kainic acid lesion in corpus Luysii. Brain Res 171:577-580, 1979
68. Hanaǧasi HA, Barlas O: Unilateral ablative lesions of the subthalamic nucleus in moderate-to-advanced Parkinson's disease. Arch Neuropsychiatry 48:114-118, 2011
69. Hariz MI: Pallidotomy for Parkinson's disease, in Lozano AM, Gildenberg PL, Tasker RR (eds): Textbook of Stereotactic and Functional Neurosurgery, ed 2. Berlin: Springer-Verlag, 2009, pp 1539-1548
70. Heimer G, Bar-Gad I, Goldberg JA, Bergman H: Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism. J Neurosci 22:7850-7855, 2002
71. Henderson JM, Annett LE, Torres EM, Dunnett SB: Behavioural effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus). Eur J Neurosci 10:689-698, 1998
72. Hirashima Y, Ikeda H, Asahi T, Shibata T, Noguchi K, Shima F, et al: Mechanical injury of the subthalamic area during stereotactic surgery followed by improvement of trunk, neck, and face tremor - case report. Neurol Med Chir (Tokyo) 45:484-486, 2005
73. Hooper AK, Okun MS, Foote KD, Fernandez HH, Jacobson C, Zeilman P, et al: Clinical cases where lesion therapy was chosen over deep brain stimulation. Stereotact Funct Neurosurg 86:147-152, 2008
74. Houdart R, Cophignon J, Dondey M: [Comparison of the effects of limited thalamic and sub-thalamic stereotaxic lesions.] Confin Neurol 27:246-250, 1966 (Fr)
75. Houdart R, Mamo H, Dondey M, Cophignon J: [Results of subthalamic coagulations in Parkinson's disease (apropos of 50 cases).] Rev Neurol (Paris) 112:521-529, 1965 (Fr)
76. Hughes B: Evaluation of the subthalamic lesion in parkinsonism, in Gillingham FJ, Donaldson IML (eds): Third Symposium on Parkinson's Disease. Edinburgh: Livingstone, 1969, pp 260-261
77. Hullay J, Velok J, Gombi R, Boczàn G: Subthalamotomy in Parkinson's disease. Confin Neurol 32:345-348, 1970
78. Hutchinson WD, Levy R, Dostrovsky JO, Lozano AM, Lang AE: Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 42:767-775, 1997
79. Hutchison WD, Allan RJ, Opitz H, Levy R, Dostrovsky JO, Lang AE, et al: Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol 44:622-628, 1998
80. Hwang YS, Shim I, Lee BB, Chang JW: Effect of subthalamic nucleus lesions in a 6-hydroxydopamine-induced rat parkinsonian model: behavioral and biochemical studies. J Neurosurg 105:284-287, 2006
81. Inzelberg R, Korczyn AD: Persistent hemiballism in Parkinson's disease. J Neurol Neurosurg Psychiatry 57:1013-1014, 1994
82. Ito Z: Stimulation and destruction of the prelemniscal radiation or its adjacent area in various extrapyramidal disorders. Confin Neurol 37:41-48, 1975
83. Jankovic J: Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord 25:527-528, 2010
84. Jeon MF, Ha Y, Cho YH, Lee BH, Park YG, Chang JW: Effect of ipsilateral subthalamic nucleus lesioning in a rat parkinsonian model: study of behavior correlated with neuronal activity in the pedunculopontine nucleus. J Neurosurg 99:762-767, 2003
85. Jourdain V, Schechtmann G: Stereotactic neurosurgery for movement disorders in a world perspective. Results from the WSSFN-supported survey. Mov Disord 27:S167, 2012
86. Jourdain VA, Grégoire L, Morissette M, Morin N, Parent M, Di Paolo T: Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy. Laboratory investigation. J Neurosurg 118:180-191, 2013
87. Keep MF, Mastrofrancesco L, Erdman D, Murphy B, Ashby LS: Gamma knife subthalamotomy for Parkinson disease: the subthalamic nucleus as a new radiosurgical target. Case report. J Neurosurg 97 (5 Suppl):592-599, 2002
88. Kishore A, Turnbull IM, Snow BJ, de la Fuente-Fernandez R, Schulzer M, Mak E, et al: Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease. Six-month follow-up with additional 1-year observations. Brain 120:729-737, 1997
89. Klostermann W, Vieregge P, Körtke D, Kömpf D: [Apraxia in eyelid opening after stereotactic sub-thalmotomy. Case report and review of the literature.] Nervenarzt 64:663-667, 1993 (Ger)
90. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al: Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349:1925-1934, 2003
91. Krack P, Limousin P, Benabid AL, Pollak P: Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet 350:1676, 1997
92. Krauss JK, Pohle T, Borremans JJ: Hemichorea and hemiballism associated with contralateral hemiparesis and ipsilateral basal ganglia lesions. Mov Disord 14:497-501, 1999
93. Künzle H: An autoradiographic analysis of the efferent connections from premotor and adjacent prefrontal regions (areas 6 and 9) in Macaca fascicularis. Brain Behav Evol 15:185-234, 1978
94. Laitinen LV: Short-term results of stereotaxic treatment for infantile cerebral palsy. Confin Neurol 26:258-263, 1965
95. Lavoie B, Parent A: Pedunculopontine nucleus in the squirrel monkey: cholinergic and glutamatergic projections to the substantia nigra. J Comp Neurol 344:232-241, 1994
96. Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F: Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 29:161-168, 2008
97. Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchison WD, Lozano AM: Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 86:249-260, 2001
98. Luquin MR, Saldise L, Guillén J, Belzunegui S, San Sebastián W, Izal A, et al: Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease? Exp Neurol 201:407-415, 2006
99. Macias R, Alvarez E, Alvarez L, Pavon N, Rodriguez-Oroz MC, Guridi J: The evolution of dyskinesias after bilateral subthalamotomy for Parkinson's disease. Mov Disord 19:S259, 2004
100. Maltête D, Chastan N, Derrey S, Debono B, Gérardin E, Lefaucheur R, et al: Microsubthalamotomy effect at day 3: screening for determinants. Mov Disord 24:286-289, 2009
101. Maltête D, Derrey S, Chastan N, Debono B, Gérardin E, Fréger P, et al: Microsubthalamotomy: an immediate predictor of long-term subthalamic stimulation efficacy in Parkinson disease. Mov Disord 23:1047-1050, 2008
102. Mamo H, Dondey M, Cophignon J, Pialoux P, Fontelle P, Houdart R: Latéro-pulsion transitoire au décours de coagulations sous-thalamiques et thalamiques chez des parkinsoniens. Rev Neurol (Paris) 112:509-520, 1965
103. Marsden CD: Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 17 (Suppl 2):S32-S44, 1994
104. Martin JP: Hemichorea resulting from a local lesion of the brain (the syndrome of the body of Luys). Brain 50:637-650, 1927
105. McCarter RJ, Walton NH, Rowan AF, Gill SS, Palomo M: Cognitive functioning after subthalamic nucleotomy for refractory Parkinson's disease. J Neurol Neurosurg Psychiatry 69:60-66, 2000
106. Meier MJ, Story J, French LA, Chou SN: Quantitative assessment of behavioral changes following subthalamotomy in the treatment of Parkinson's disease. Confin Neurol 27:154-161, 1966
107. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, et al: Priorities in Parkinson's disease research. Nat Rev Drug Discov 10:377-393, 2011
108. Melamed E, Korn-Lubetzki I, Reches A, Siew F: Hemiballismus: detection of focal hemorrhage in subthalamic nucleus by CT scan. Ann Neurol 4:582, 1978
109. Merello M, Perez-Lloret S, Antico J, Obeso JA: Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. J Neurol Neurosurg Psychiatry 77:172-174, 2006
110. Merello M, Tenca E, Pérez Lloret S, Martín ME, Bruno V, Cavanagh S, et al: Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study. Br J Neurosurg 22:415-422, 2008
111. Mitchell IJ, Sambrook MA, Crossman AR: Subcortical changes in the regional uptake of [3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-aminobutyric acid antagonist into the subthalamic nucleus. Brain 108:405-422, 1985
112. Mundinger F: Results of 500 subthalamotomies in the region of the zona incerta, in Gillingham FJ, Donaldson IML (eds): Third Symposium on Parkinson's Disease. Edinburgh: Livingstone, 1969, pp 261-265
113. Mundinger F: Stereotaxic interventions on the zona incerta area for treatment of extrapyramidal motor disturbances and their results. Confin Neurol 26:222-230, 1965
114. Murer MG, Riquelme LA, Tseng KY, Pazo JH: Substantia nigra pars reticulata single unit activity in normal and 60HDA-lesioned rats: effects of intrastriatal apomorphine and subthalamic lesions. Synapse 27:278-293, 1997
115. Nakao N, Nakai E, Nakai K, Itakura T: Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann Neurol 45:640-651, 1999
116. Narabayashi H, Kubota K: Reconsideration of ventrolateral thalamotomy for hyperkinesis. Prog Brain Res 21:339-349, 1966
117. Ni Z, Bouali-Benazzouz R, Gao D, Benabid AL, Benazzouz A: Changes in the firing pattern of globus pallidus neurons after the degeneration of nigrostriatal pathway are mediated by the subthalamic nucleus in the rat. Eur J Neurosci 12:4338-4344, 2000
118. Nishioka H, Taguchi T, Nanri K, Ikeda Y: Transient hemiballism caused by a small lesion of the subthalamic nucleus. J Clin Neurosci 15:1416-1418, 2008
119. Nittner K: The combined thalamo-subthalamotomy. Confin Neurol 32:93-99, 1970
120. Obeso JA, Alvarez L, Guridi J, Teijeiro J, Juncos JL, Rodriguez MC, et al: Lesion of the subthalamic nucleus (STN) in Parkinson's disease. Neurology 48:A138, 1997
121. Obeso JA, Alvarez L, Macias R, Pavon N, Lopez G, Rodriguez-Rojas R, et al: Subthalamotomy for Parkinson's disease, in Lozano AM, Gildenberg PL, Tasker RR (eds): Textbook of Stereotactic and Functional Neurosurgery, ed 2. Berlin: Springer-Verlag, 2011, pp 1569-1576
122. Obeso JA, Jahanshahi M, Alvarez L, Macias R, Pedroso I, Wilkinson L, et al: What can man do without basal ganglia motor output? The effect of combined unilateral subthalamotomy and pallidotomy in a patient with Parkinson's disease. Exp Neurol 220:283-292, 2009
123. Pahwa R, Wilkinson SB, Overman J, Lyons KE: Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg 99:71-77, 2003
124. Papa SM, Desimone R, Fiorani M, Oldfield EH: Internal globus pallidus discharge is nearly suppressed during levodopainduced dyskinesias. Ann Neurol 46:732-738, 1999
125. Paquet M, Tremblay M, Soghomonian JJ, Smith Y: AMPA and NMDA glutamate receptor subunits in midbrain dopaminergic neurons in the squirrel monkey: an immunohistochemical and in situ hybridization study. J Neurosci 17:1377-1396, 1997
126. Park HK, Kim HJ, Kim SJ, Kim JS, Shin HW, Kim JS: From Jekyll to Hyde after limbic subthalamic nucleus infarction. Neurology 77:82-84, 2011
127. Park YS, Jeon MF, Lee BH, Chang JW: Lesion of subthalamic nucleus in parkinsonian rats: effects of dopamine d(1) and d(2) receptor agonists on the neuronal activities of the substantia nigra pars reticulata. J Korean Neurosurg Soc 42:455-461, 2007
128. Parkin S, Nandi D, Giladi N, Joint C, Gregory R, Bain P, et al: Lesioning the subthalamic nucleus in the treatment of Parkinson's disease. Stereotact Funct Neurosurg 77:68-72, 2001
129. Patel NK, Heywood P, O'Sullivan K, Love S, Gill SS: MRI-directed subthalamic nucleus surgery for Parkinson's disease. Stereotact Funct Neurosurg 78:132-145, 2002
130. Patel NK, Heywood P, O'Sullivan K, McCarter R, Love S, Gill SS: Unilateral subthalamotomy in the treatment of Parkinson's disease. Brain 126:1136-1145, 2003
131. Paul G, Meissner W, Rein S, Harnack D, Winter C, Hosmann K, et al: Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 185:272-280, 2004
132. Périer C, Marin C, Jimenez A, Bonastre M, Tolosa E, Hirsch EC: Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats. J Neurochem 86:1328-1337, 2003
133. Piallat B, Benazzouz A, Benabid AL: Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 8:1408-1414, 1996
134. Postuma RB, Lang AE: Hemiballism: revisiting a classic disorder. Lancet Neurol 2:661-668, 2003
135. Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt MG, Eidelberg D: Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. Clinical article. J Neurosurg 110:1278-1282, 2009
136. Price RH Jr, Hollingsworth Z, Young AB, Penney JB Jr: Excitatory amino acid receptor regulation after subthalamic nucleus lesions in the rat. Brain Res 602:157-160, 1993
137. Remple MS, Bradenham CH, Kao CC, Charles PD, Neimat JS, Konrad PE: Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression. Mov Disord 26:1657-1662, 2011
138. Renard D, Le Floch A, Castelnovo G, Collombier L, Kotzki PO, Labauge P: Hemiballism due to an ipsilateral subthalamic nucleus lesion. J Neurol 258:507-509, 2011
139. Ristic A, Marinkovic J, Dragasevic N, Stanisavljevic D, Kostić V: Long-term prognosis of vascular hemiballismus. Stroke 33:2109-2111, 2002
140. Rizelio V, Szawka RE, Xavier LL, Achaval M, Rigon P, Saur L, et al: Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease. Braz J Med Biol Res 43:85-95, 2010
141. Rodriguez MC, Guridi OJ, Alvarez L, Mewes K, Macias R, Vitek J, et al: The subthalamic nucleus and tremor in Parkinson's disease. Mov Disord 13 (Suppl 3):111-118, 1998
142. Rodriguez MC, Obeso JA, Olanow CW: Subthalamic nucle-us- mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44 (3 Suppl 1):S175-S188, 1998
143. Rogano LA, Assis M, Teixeira MJ: [Horner syndrome after stereotactic Parkinson disease surgery.] Arq Neuropsiquiatr 61 (2A):248-249, 2003 (Portugese)
144. Ryan LJ, Sanders DJ: Subthalamic nucleus lesion regularizes firing patterns in globus pallidus and substantia nigra pars reticulata neurons in rats. Brain Res 626:327-331, 1993
145. Schechtmann G, Jourdain V: Health economics and surgical treatment for Parkinson's disease in a world perspective. Mov Disord 28 Suppl 1:1299, 2013 (Abstract)
146. Selby G: Stereotactic surgery for the relief of Parkinson's disease. 1. A critical review. J Neurol Sci 5:315-342, 1967
147. Sellal F, Hirsch E, Lisovoski F, Mutschler V, Collard M, Marescaux C: Contralateral disappearance of parkinsonian signs after subthalamic hematoma. Neurology 42:255-256, 1992
148. Shimo Y, Wichmann T: Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum. Eur J Neurosci 29:104-113, 2009
149. Smith ID, Grace AA: Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse 12: 287-303, 1992
150. Smith Y, Charara A, Parent A: Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J Comp Neurol 364:231-253, 1996
151. Smith Y, Parent A: Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res 453:353-356, 1988
152. Spiegel EA, Wycis HT, Szekely EG, Adams DJ, Flanagan M, Baird HW III: Campotomy in various extrapyramidal disorders. J Neurosurg 20:871-884, 1963
153. Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V, et al: Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 249:759-766, 2002
154. Story JL, French LA, Chou SN, Meier MJ: Experiences with subthalamic lesions in patients with movement disorders. Confin Neurol 26:218-221, 1965
155. Struppler A, Burg D, Lücking CH, Velho F: The mode of innervation following thalamotomy and subthalamotomy. Confin Neurol 36:347-354, 1974
156. Strutt AM, Simpson R, Jankovic J, York MK: Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol 19:121-127, 2012
157. Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng HM, Yen RF, et al: Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol 50:514-520, 2001
158. Su PC, Tseng HM: Subthalamotomy for end-stage severe Parkinson's disease. Mov Disord 17:625-627, 2002 (Letter)
159. Su PC, Tseng HM, Liou HH: Postural asymmetries following unilateral subthalomotomy for advanced Parkinson's disease. Mov Disord 17:191-194, 2002
160. Su PC, Tseng HM, Liu HM, Yen RF, Liou HH: Subthalamotomy for advanced Parkinson disease. J Neurosurg 97:598-606, 2002
161. Su PC, Tseng HM, Liu HM, Yen RF, Liou HH: Treatment of advanced Parkinson's disease by subthalamotomy: one-year results. Mov Disord 18:531-538, 2003
162. Suarez JI, Metman LV, Reich SG, Dougherty PM, Hallett M, Lenz FA: Pallidotomy for hemiballismus: efficacy and characteristics of neuronal activity. Ann Neurol 42:807-811, 1997
163. Tachibana Y, Iwamuro H, Kita H, Takada M, Nambu A: Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia. Eur J Neurosci 34:1470-1484, 2011
164. Takada M, Matsumura M, Kojima J, Yamaji Y, Inase M, Tokuno H, et al: Protection against dopaminergic nigrostriatal cell death by excitatory input ablation. Eur J Neurosci 12:1771-1780, 2000
165. Tarsy D: Does subthalamotomy have a place in the treatment of Parkinson's disease? J Neurol Neurosurg Psychiatry 80:939-940, 2009
166. Touchon JC, Moore C, Frederickson J, Meshul CK: Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopa-mine- treated rats: effects on striatal glutamate and apomor-phine- induced contralateral rotations. Synapse 51:287-298, 2004
167. Toulouse A, Sullivan AM: Progress in Parkinson's disease - where do we stand? Prog Neurobiol 85:376-392, 2008
168. Trost M, Su PC, Barnes A, Su SL, Yen RF, Tseng HM, et al: Evolving metabolic changes during the first postoperative year after subthalamotomy. J Neurosurg 99:872-878, 2003
169. Tseng HM, Su PC, Liu HM: Persistent hemiballism after subthalamotomy: the size of the lesion matters more than the location. Mov Disord 18:1209-1211, 2003
170. Tseng HM, Su PC, Liu HM, Liou HH, Yen RF: Bilateral subthalamotomy for advanced Parkinson disease. Surg Neurol 68 (Suppl 1):S43-S51, 2007
171. Tseng KY, Kasanetz F, Kargieman L, Pazo JH, Murer MG, Riquelme LA: Subthalamic nucleus lesions reduce low frequency oscillatory firing of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease. Brain Res 904:93-103, 2001
172. Umemura A, Oka Y, Okita K, Matsukawa N, Yamada K: Subthalamic nucleus stimulation for Parkinson disease with severe medication-induced hallucinations or delusions. Clinical article. J Neurosurg 114:1701-1705, 2011
173. Velasco FC, Molina-Negro P, Bertrand C, Hardy J: Further definition of the subthalamic target for arrest of tremor. J Neurosurg 36:184-191, 1972
174. Vidaković A, Dragasević N, Kostić VS: Hemiballism: report of 25 cases. J Neurol Neurosurg Psychiatry 57:945-949, 1994
175. Vilela Filho O, da Silva DJ: Unilateral subthalamic nucleus lesioning: a safe and effective treatment for Parkinson's disease. Arq Neuropsiquiatr 60:935-948, 2002
176. Vilela Filho O, Silva DJ, Souza HA, Cavalcante JE, Sousa JT, Ferraz FP, et al: Stereotactic subthalamic nucleus lesioning for the treatment of Parkinson's disease. Stereotact Funct Neurosurg 77:79-86, 2001
177. Vitek JL, Bakay RAE, Freeman A, Evatt M, Green J, McDonald W, et al: Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 53:558-569, 2003
178. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, et al: Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 8:1140-1149, 2009
179. Walker RH, Koch RJ, Moore C, Meshul CK: Subthalamic nucleus stimulation and lesioning have distinct state-dependent effects upon striatal dopamine metabolism. Synapse 63:136-146, 2009
180. Walker RH, Koch RJ, Sweeney JE, Moore C, Meshul CK: Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatum. Neuroreport 20:770-775, 2009
181. Wallace BA, Ashkan K, Heise CE, Foote KD, Torres N, Mitrofanis J, et al: Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130:2129-2145, 2007
182. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, et al: Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301:63-73, 2009
183. Wertheimer P, Bourret J, Lapraz C: [Apropos of a case of volitional postural dyskinesia treated with thalamic subthalamic leucotomy.] Rev Prat 102:481-486, 1960 (Fr)
184. Whittier JR, Mettler FA: Studies on the subthalamus of the rhesus monkey; hyperkinesia and other physiologic effects of subthalamic lesions; with special reference to the subthalamic nucleus of Luys. J Comp Neurol 90:319-372, 1949
185. Wichmann T, Bergman H, DeLong MR: The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 72:521-530, 1994
186. Wichmann T, Bergman H, Starr PA, Subramanian T, Watts RL, DeLong MR: Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. Exp Brain Res 125:397-409, 1999
187. Winter C, Hosmann K, Harnack D, Meissner W, Paul G, Morgenstern R, et al: Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease. Synapse 60:69-80, 2006
188. Witjas T, Azulay JP, Eusebio A, Pergut JC, Régis J: Gamma knife subthalamotomy in Parkinson's disease: long-term follow-up. Mov Disord 24 Suppl 1:S477, 2009 (Abstract)
189. Wong SH, Eldridge PR, Duffy A, Fox SH, Varma TRK, Fletcher NA: Two cases of unexpected long-term improvement of Parkinson's disease after subthalamic nucleus deep brain stimulation removal. Br J Neurosurg 25:281-283, 2011
190. Yamada A, Takeuchi H, Miki H: [Unilateral abolition of parkinsonian rigidity after subthalamic nucleus hemorrhage.] Rinsho Shinkeigaku 32:887-889, 1992 (Jpn)
191. Zahr NM, Martin LP, Waszczak BL: Subthalamic nucleus lesions alter basal and dopamine agonist stimulated electrophysiological output from the rat basal ganglia. Synapse 54:119-128, 2004
192. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU: MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine- induced parkinsonism in primates. J Neurochem 59:733-739, 1992